MedPath
EMA Product

Exviera

Product approved by European Medicines Agency (EU)

Basic Information

Exviera

Regulatory Information

EMEA/H/C/003837

Withdrawn

January 14, 2015

November 20, 2004

26

April 13, 2023

Company Information

United Kingdom

Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

ABBVIE LTD

Drug Classification

Accelerated Assessment

Active Ingredients

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Exviera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Exviera. For practical information about using Exviera, patients should read the package leaflet or contact their doctor or pharmacist.

© Copyright 2025. All Rights Reserved by MedPath